Two boxes, two names, one molecule. The confusion is entirely a product of how drugs are approved and paid for in the United States, and once you see the structure it stops being confusing.

The short answer

Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, given as a once-weekly subcutaneous injection, in the same six strengths.

The difference is the FDA-approved indication printed on each label. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management and for obstructive sleep apnea in adults with obesity.

That single distinction determines which one you can be prescribed, which one your insurance will consider, and what you pay.

What each one is approved for

Mounjaro, first approved in May 2022, is indicated "as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus."

Weight loss appears throughout the Mounjaro clinical data, and it is one of the reasons the drug became so widely known. It is still not what the label approves it for.

Zepbound was approved on November 8, 2023 for chronic weight management in adults with:

  • A BMI of 30 or greater, or
  • A BMI of 27 or greater plus at least one weight-related condition, such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease

alongside a reduced-calorie diet and increased physical activity. In December 2024 the FDA added a second indication: moderate-to-severe obstructive sleep apnea in adults with obesity.

Notice the overlap. Type 2 diabetes appears on the Zepbound label as a qualifying comorbidity for the weight indication, not as the condition being treated. That subtlety is where most of the real-world coverage disputes originate.

Is the drug itself identical?

Yes, on every dimension that affects how it works:

  • Active ingredient: tirzepatide, a dual GIP and GLP-1 receptor agonist, in both.
  • Manufacturer: Eli Lilly, both.
  • Route and frequency: subcutaneous injection, once weekly, both.
  • Strengths: 2.5, 5, 7.5, 10, 12.5, and 15 mg, both.
  • Titration: start at 2.5 mg for four weeks, then step up in 2.5 mg increments no more often than every four weeks, both. In both labels the 2.5 mg starting dose exists to improve tolerability and is not intended to produce the treatment effect.
  • Boxed warning: thyroid C-cell tumours in rats, with contraindication in anyone who has a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Identical in both.

If someone tells you one "works better," the pharmacology gives no basis for it. Dose, duration, diet, activity, and ordinary week-to-week variability explain those reports far more plausibly. Our guide to how tirzepatide works covers the dual-receptor mechanism that both products share.

Why does one molecule have two names?

Because the FDA approves indications, not molecules, and a manufacturer that wants a second indication studied in a different population files a separate application.

Separate brands then bring practical advantages. Each label can carry its own dosing guidance, its own trial data, and its own patient materials. Prescribing and claims processing can distinguish a diabetes prescription from a weight prescription. And each brand can have its own price and savings program, which matters a great deal given that many plans cover the two categories very differently.

The same pattern already exists elsewhere in this drug class. Semaglutide is sold as Ozempic for type 2 diabetes and as Wegovy for weight management, and our sister site covers that pair at ozempic.md.

The insurance problem, in both directions

This is where the distinction stops being administrative and starts costing money.

Coverage for type 2 diabetes medication is broad and long-established. Coverage for weight-management medication is not. Many commercial plans exclude anti-obesity drugs outright, and Medicare Part D has historically been restricted from covering drugs prescribed solely for weight loss.

The result is a mismatch that catches people from both sides:

  • If you have type 2 diabetes, Mounjaro is usually the covered route. Plans frequently refuse Zepbound when a type 2 diabetes diagnosis is on file, on the reasoning that a covered diabetes option already exists.
  • If you do not have type 2 diabetes, Mounjaro will generally not be covered at all, because you do not meet its indication. Zepbound is the correct product, and whether it is covered depends entirely on whether your plan includes weight-management drugs.

The practical first step is not to choose a brand. It is to find out whether your plan covers anti-obesity medication at all. That single answer determines the entire path. Our cost and insurance guide covers prior authorization, appeals, and self-pay options in detail.

The sleep apnea indication

The December 2024 approval is the one genuine clinical capability Zepbound has that Mounjaro does not, and it is worth understanding because it can open a coverage door.

It rests on SURMOUNT-OSA, two phase 3 trials in adults with moderate-to-severe obstructive sleep apnea and obesity, using 10 mg or 15 mg tirzepatide over one year. One trial enrolled 234 people not using positive airway pressure therapy; the other enrolled 235 people who were.

In the group not using PAP, tirzepatide produced roughly 25 fewer apnea-hypopnea events per hour, compared with about 5 fewer on placebo. Reported remission rates for moderate-to-severe OSA in that group ranged from roughly 42% to 51%.

Two things this does not mean. It is not a replacement for CPAP in people who are doing well on it, and it is not indicated for sleep apnea in people without obesity. It is a treatment option for a specific overlap, and the trials were designed around that overlap.

If you have both obesity and diagnosed moderate-to-severe OSA, this indication is worth raising explicitly, because it can qualify a Zepbound prescription that would otherwise be denied as weight-loss-only.

Should you switch from one to the other?

Clinically, switching is not really a switch. The dose transfers one-to-one and there is no re-titration required simply because the box changed.

The reasons to move are practical rather than medical:

  • Coverage. Your plan pays for one and not the other.
  • Indication accuracy. You do not have type 2 diabetes, so Zepbound is the label that actually matches your situation.
  • Supply. Availability of specific strengths has fluctuated for both products.
  • Savings programs. Manufacturer and self-pay pricing have differed between the two brands, and both have changed repeatedly.

There is no clinical reason to switch if what you have is working and covered. If you do move, do not skip doses in the gap; discuss timing with your prescriber so the weekly schedule stays intact.

What is the same either way

Everything about living with the drug:

  • Side effects. Nausea, diarrhoea, vomiting, constipation, and abdominal discomfort are the common ones, most prominent after each dose increase. Our guide to managing side effects applies equally to both.
  • Injection technique and sites. Identical. See injection sites.
  • The titration schedule and the four-week minimum between increases.
  • The contraindications, including medullary thyroid carcinoma history and MEN 2.
  • The need to tell any surgeon or anaesthetist that you take it, because delayed gastric emptying affects sedation planning.
  • The results you can expect, which our month-by-month timeline covers.

How to talk to your prescriber

Four questions get to an answer faster than debating brands:

  1. Do I have a type 2 diabetes diagnosis on file? This is the single largest determinant of which route is open.
  2. Does my plan cover anti-obesity medication? Ask the plan directly, not the pharmacy counter.
  3. Do I have diagnosed moderate-to-severe obstructive sleep apnea? If so, that is a separate approved indication and a separate coverage argument.
  4. If the first request is denied, what does the appeal require? Prior authorization criteria are usually specific and documentable in advance.

The medicine in the pen is the same either way. What you are actually negotiating is which label gets you access to it.

Last updated: August 2026. This article is for informational purposes only and does not constitute medical advice. Indications, pricing, and coverage change frequently. Do not start, stop, or switch any prescription medication without speaking to your prescriber.